Clinical Trial Update: Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl [Phase 3]

View source ↗

Summary

Phase 3 dose-optimization trial in adolescents (13-17) with ADHD evaluating extended-release guanfacine HCl; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• guanfacine HCl (guanfacine)

Snippet

Sponsor: Shire | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-05-23